March 21, 2007
New FDA Advisory Board Rules on Financial Conflict of Interest
Article in the New York Times -- F.D.A. Rule Limits Role of Advisers Tied to Industry, by Gardiner Harris. Here's an excerpt:
Expert government advisers who receive money from a drug or device maker would be barred for the first time from voting on whether to approve that company’s products under new rules announced Wednesday for the F.D.A.’s powerful advisory committees.
Indeed, such advisers who receive more than $50,000 from a company or a competitor whose product is being discussed would no longer be allowed to serve on the committees, though those who receive less than that amount in the prior year can join a committee and participate in its discussions.
A “significant number” of the agency’s present advisers would be affected by the new policy, said the F.D.A. acting deputy commissioner, Randall Lutter, although he would not say how many. The rules are among the first major changes made by Dr. Andrew C. von Eschenbach since he was confirmed as commissioner of food and drugs late last year.
Advisory boards recommend drugs for approval and, in rare cases, removal, and their votes can have enormous influence on drug company fortunes.
Here's a link to the Washington Post story.
TrackBack URL for this entry:
Listed below are links to weblogs that reference New FDA Advisory Board Rules on Financial Conflict of Interest: